Management of connective tissue disease-associated interstitial lung disease.

[1]  D. K. Kim,et al.  Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2016 , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  M. Aringer,et al.  Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. , 2014, Rheumatology.

[3]  A. Young,et al.  Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. , 2014, Rheumatology.

[4]  M. Abrahamowicz,et al.  Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort , 2014, Scandinavian journal of rheumatology.

[5]  Kazuhisa Takahashi,et al.  Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis , 2014, BMJ Open.

[6]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[7]  M. Moradi-Lakeh,et al.  Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—a retrospective study , 2014, Rheumatology International.

[8]  B. Haraoui,et al.  Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. , 2014, Seminars in arthritis and rheumatism.

[9]  A. Young,et al.  O36. Rheumatoid-Arthritis-Related Interstitial Lung Disease: Association Between Biologic Therapy and Survival , 2014 .

[10]  M. Kurosaka,et al.  Gastroesophageal reflux disease in patients with rheumatoid arthritis , 2014, Modern rheumatology.

[11]  C. Bridges,et al.  Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2014 , 2014, Annals of internal medicine.

[12]  H. Palevsky,et al.  Pulmonary arterial hypertension related to connective tissue disease: a review. , 2014, Rheumatic diseases clinics of North America.

[13]  S. Nathan,et al.  Pulmonary hypertension due to lung disease and/or hypoxia. , 2013, Clinics in chest medicine.

[14]  S. Birring,et al.  Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. , 2014, American journal of respiratory and critical care medicine.

[15]  A. Nicholson,et al.  Rituximab in severe, treatment‐refractory interstitial lung disease , 2014, Respirology.

[16]  Meng Xu,et al.  A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. , 2013, Respiratory medicine.

[17]  Kazuhisa Takahashi,et al.  Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. , 2013, Respiratory investigation.

[18]  S. Gabriel,et al.  Incidence and Time Trends of Herpes Zoster in Rheumatoid Arthritis: A Population‐Based Cohort Study , 2013, Arthritis care & research.

[19]  Sally J. Singh,et al.  Pulmonary Rehabilitation and Interstitial Lung Disease: AIDING THE REFERRAL DECISION , 2013, Journal of cardiopulmonary rehabilitation and prevention.

[20]  R. D. du Bois,et al.  Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease , 2013, The Journal of Rheumatology.

[21]  F. Meloni,et al.  Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease , 2013, The Journal of Rheumatology.

[22]  S. Yamasaki,et al.  Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases , 2013, Modern rheumatology.

[23]  T. Hartman,et al.  Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia , 2012 .

[24]  C. Bombardier,et al.  Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety , 2012, The Journal of Rheumatology.

[25]  C. Bombardier,et al.  Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs , 2012, The Journal of Rheumatology.

[26]  L. Trinquart,et al.  One-Year Experience With High-Emergency Lung Transplantation in France , 2012, Transplantation.

[27]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[28]  C. Kalogeropoulou,et al.  Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. , 2012, Clinical and experimental rheumatology.

[29]  D. Hansell,et al.  Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy , 2012, European Respiratory Journal.

[30]  S. Sungkanuparph,et al.  Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. , 2011, Seminars in arthritis and rheumatism.

[31]  C. Spettell,et al.  The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study , 2011, Arthritis research & therapy.

[32]  A. Montgomery,et al.  Ambulatory oxygen in interstitial lung disease , 2011, European Respiratory Journal.

[33]  S. Nanjo,et al.  Clinical Features and Outcome of Acute Exacerbation of Interstitial Pneumonia: Collagen Vascular Diseases-Related versus Idiopathic , 2011, Respiration.

[34]  P. Sfikakis,et al.  Biological treatments and connective tissue disease associated interstitial lung disease , 2011, Current opinion in pulmonary medicine.

[35]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[36]  Jonathan G. Goldin,et al.  Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. , 2011, Arthritis and rheumatism.

[37]  J. Ioannidis,et al.  EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2010, Annals of the rheumatic diseases.

[38]  P. Sfikakis,et al.  TNF-α antagonists beyond approved indications: stories of success and prospects for the future. , 2010, QJM : monthly journal of the Association of Physicians.

[39]  P. Emery,et al.  Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. , 2010, Arthritis and rheumatism.

[40]  M. Lunt,et al.  Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register , 2010 .

[41]  M. Fishbein,et al.  Systemic sclerosis and bilateral lung transplantation: a single centre experience , 2010, European Respiratory Journal.

[42]  C. Kalogeropoulou,et al.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study , 2009, Rheumatology.

[43]  M. Feldmann,et al.  Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[44]  J. Gran,et al.  Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. , 2009, Rheumatology.

[45]  H. Yamanaka,et al.  Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan , 2009, The Journal of Rheumatology.

[46]  T. Colby,et al.  Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases , 2009, Respiratory Medicine.

[47]  P. Merkel,et al.  B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. , 2009, Arthritis and rheumatism.

[48]  W. Boersma,et al.  Rituximab in life threatening antisynthetase syndrome , 2009, Rheumatology International.

[49]  L. Mouthon,et al.  Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. , 2008, The Journal of rheumatology.

[50]  C. Goss,et al.  Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. , 2008, Chest.

[51]  R. Elashoff,et al.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. , 2007, American journal of respiratory and critical care medicine.

[52]  H. Yamanaka,et al.  Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[53]  P. Voulgari,et al.  Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. , 2006, Seminars in arthritis and rheumatism.

[54]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[55]  J. Orens,et al.  Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. , 2006, Arthritis and rheumatism.

[56]  N. Kamatani,et al.  Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease , 2006, Modern rheumatology.

[57]  S. Liossis,et al.  Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. , 2006, Rheumatology.

[58]  D. Lynch,et al.  Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. , 2006, Chest.

[59]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[60]  N. Miyasaka,et al.  Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. , 2005, Clinical and experimental rheumatology.

[61]  C. Cooper,et al.  Use of Oral Corticosteroids and Risk of Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  S. Sereika,et al.  Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. , 2005, Arthritis and rheumatism.

[63]  N. Miyasaka,et al.  Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants , 2005, Autoimmunity.

[64]  A. Carmichael,et al.  Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: A strategy for prevention , 2004, BMC infectious diseases.

[65]  Douglas Curran-Everett,et al.  Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. , 2004, Chest.

[66]  U. Lalloo,et al.  Experience with azathioprine in systemic sclerosis associated with interstitial lung disease , 2004, Clinical Rheumatology.

[67]  S. Shapiro.  Management of pulmonary hypertension resulting from interstitial lung disease , 2003, Current opinion in pulmonary medicine.

[68]  M. Sutton,et al.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. , 2003, American journal of respiratory and critical care medicine.

[69]  T. Medsger,et al.  Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. , 2003, Arthritis and rheumatism.

[70]  K. Sepkowitz.  Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  Aminah Khan and Sami M. Shimi.  Gastro-oesophageal reflux disease , 2000, The Lancet.

[72]  R. Wise,et al.  Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis , 2000, Annals of Internal Medicine.

[73]  N. Kamatani,et al.  [Nation-wide survey for the treatment with cyclosporin A of interstitial pneumonia associated with collagen diseases]. , 1999, Ryumachi. [Rheumatism].

[74]  W. Seeger,et al.  Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.

[75]  T. Medsger,et al.  Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. , 1998, Arthritis and rheumatism.

[76]  W. Gross,et al.  Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. , 1998, Arthritis and rheumatism.

[77]  J. Kremer,et al.  Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. , 1997, Arthritis and rheumatism.

[78]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[79]  P. Kahrilas.  Gastroesophageal reflux disease. , 1996, JAMA.

[80]  C. V. Strimlan.  Interstitial lung disease and primary Sjögren's syndrome: clinical-pathological evaluation and response to treatment. , 1996, American journal of respiratory and critical care medicine.

[81]  R. Balk,et al.  The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. , 1995, The Journal of rheumatology.

[82]  T. Medsger,et al.  Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. , 1994, Arthritis and rheumatism.

[83]  A. Lundin,et al.  Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. , 1994, Arthritis and rheumatism.

[84]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[85]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .

[86]  T. Kurita,et al.  The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. , 2015, Rheumatology.

[87]  D. Borderie,et al.  High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. , 2008, Arthritis and rheumatism.

[88]  Y. Yamasaki,et al.  Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. , 2007, Rheumatology.

[89]  T. Starzl,et al.  Tacrolimus in refractory polymyositis with interstitial lung disease. , 1999, Lancet.

[90]  P. Saldiva,et al.  Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. , 1996, American journal of respiratory and critical care medicine.

[91]  R. Silver,et al.  Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. , 1993, The Journal of rheumatology.

[92]  Professor László Czirják.  The gastro-intestinal tract in systemic sclerosis , 2022 .